Recently, Deep Intelligent Pharma (DIP), a global leading AI-driven drug discovery and development platform, completed its Series C financing, raising nearly $50 million USD. This round of financing was led by CDH Vantone, with follow-on investments from existing shareholders Newding Capital and Sequoia China. The funds will primarily be used for the research and iteration of the full-process autonomous clinical system and the expansion of its global commercialization network, accelerating the generational leap from being a "support tool" to a "decision-making infrastructure."
Deep Intelligent Pharma (DIP), founded in 2017, is a technology company dedicated to using artificial intelligence to reshape the entire drug research and development process. The company has gathered top AI scientists and seasoned clinical experts from around the world. Through its self-developed Agent cluster and Cognitive Operating System, DIP provides global pharmaceutical companies with a full-stack intelligent solution from pre-clinical stages to post-launch, striving to make new drug development more precise, efficient, and economical.
CDH Vantone commented: "What Deep Intelligent Pharma exhibits is not a single technological tool, but a fundamental reconstruction of the underlying logic of pharmaceutical R&D. The moat they have built using 'atomic agents' allows us to see the possibility of thoroughly transforming the CRO industry from 'labor-intensive' to 'technology-intensive.' In the global race for AI implementation in healthcare, Deep Intelligent Pharma has already secured a strategically valuable ecological position."
Llinks acting as the legal counsel for CDH Vantone, provided professional legal services for this investment, leveraging its extensive project experience in the investment and financing sector.
Llinks Engagement Team
Selena She, Partner
Colin Shi, Partner
Jerome Tang, Associate
